We’re pleased to welcome Kevin Sayer to our Board of Directors. As former CEO and current Executive Chairman of Dexcom, Kevin brings a strong record of advancing health technology and driving growth, & his expertise will be invaluable as we continue to pioneer innovations to shape the next era of #CancerCare. Details: bit.ly/4AdYaA9

Our Shield™ blood test has received the 2026 #PrixGalien USA Award for Best Medical Technology! The award recognizes Shield’s impact in expanding patient choice and increasing #ColorectalCancer screening participation, celebrating the innovative science and dedication behind making CRC screening more accessible & closing the nation’s screening gap. Details: bit.ly/4z32JMP

We applaud Pennsylvania’s new law aligning coverage with the latest @AmericanCancer & @NCCN guidelines, expanding access to screening innovations like our Shield™ #BloodTest with no cost-sharing for approximately 2 million screening-eligible Pennsylvanians. More: bit.ly/4zj0ENC

Strong collaborations drive new possibilities in #CancerCare. At #ESMO26, we, along with our research collaborators, will present 25 abstracts, including 5 rapid oral presentations, exploring advances in liquid biopsy across lung, colorectal, & gastric cancers. Reflecting the strength of our biopharma, academic, & public-private partnerships, these findings expand the evidence across MRD surveillance, treatment response, and resistance research, advancing our understanding of how genomic and epigenomic insights can inform cancer care. Details: bit.ly/486gejw

New from @MoffittNews @GuardantHealth researchers 💡 In IDH1+ aCCA, immunotx added to GemCis was assoc w/ inferior rwOS. Findings support obtaining ctDNA-based CGP before initiating 1L therapy & underscore the need for prospective studies. acsjournals.onlinelibrary.wi… @OncoAlert

#NewData reinforces the potential of Shield™ to close gaps in #ColorectalCancer screening, with 99% screening adherence in two rural clinics serving medically underserved communities and modeling results projecting more colorectal cancer deaths averted with blood-based screening than stool-based tests. Presented with our research collaborators at #ACG2026, this new modeling data builds on the growing evidence supporting Shield’s role in expanding screening participation and improving health outcomes. More: bit.ly/4s7DwyB

Guardant360® CDx’s 31st companion diagnostic approval marks another #Milestone in its growing role in cancer care. Guardant360 CDx has received approval in Europe as a companion diagnostic to identify patients with ER-positive, HER2-negative locally advanced or metastatic breast cancer who may benefit from @AstraZeneca's ETCAMAH™ (camizestrant). Following approvals in the U.S. and Japan, this milestone reinforces our commitment to enabling practice-changing ongoing monitoring across the world’s largest healthcare markets. More: bit.ly/4AXzGfx

"This is a landmark change in terms of how cancer is managed." @GuardantHealth Co-CEO Helmy Eltoukhy celebrates a key FDA approval for his company's blood-based biopsy test for breast cancer treatment guidance: cnbc.com/video/2026/09/25/gu…

Understanding melanoma recurrence risk after surgery can help shape what comes next for patients. New results from the COSMOS-MEL01 study, published in @CRC_AACR, expand the evidence supporting Guardant Reveal® for molecular residual disease detection and recurrence monitoring in melanoma. The study demonstrated 81% sensitivity for distant recurrence and 100% post-treatment specificity, highlighting the potential of Reveal to inform more personalized surveillance strategies. More: bit.ly/3Vt96uM

#AI is everywhere—but where is it making an impact in drug discovery and development? At the 16th World Clinical Biomarkers & Companion Diagnostics Summit, we’ll share how InfinityAI and our multiomic data are helping researchers navigate complex biological datasets, accelerate hypothesis generation, and uncover new opportunities for therapeutic development. Join us in Boston: world-cdx.com/

Our Chairman and co-CEO Helmy Eltoukhy joined @CNBC this morning to discuss how blood-based testing can help physicians identify molecular resistance in metastatic #BreastCancer—moving cancer care from one step behind to one step ahead.

“Every great advancement in medicine has come from seeing something that was once invisible.” @Helmy_L2K, CEO of @GuardantHealth, joined me at @spc to talk about the journey from liquid biopsy to early cancer detection, what makes diagnostics such a difficult business, and how AI could help unlock new applications far beyond cancer.

We’re proud to sponsor the 2026 @NCQA Health Innovation Summit in Atlanta. We look forward to connecting with leaders advancing quality, digital transformation, and innovation across healthcare, and discussing how blood-based #ColorectalCancer screening can accelerate adoption and reduce barriers in population health strategies. #NCQASummit

#NewResearch in @JCOPO_ASCO highlights the prognostic value of tissue-free MRD testing. In an analysis of samples from the SUCCESS-A trial, Guardant Reveal® detected molecular residual disease approximately two years after adjuvant chemotherapy, with ctDNA positivity strongly associated with later distant recurrence. Read more: bit.ly/4gY28pT

#Coverage for the Shield™ blood test for #ColorectalCancer screening continues to expand. Starting January 1, 2027, @evicorehc —the second-largest national medical benefit manager in the U.S.—will cover Shield for eligible policyholders, bringing Shield coverage to approximately 94 million Americans ages 45 and older. Details: bit.ly/4htyw3J

How can a blood test help clinicians monitor changes in cancer? On @CNN's The Situation Room this morning, our Chairman and co-CEO Helmy Eltoukhy joined @PamelaBrownCNN to discuss the first-of-its-kind FDA approval of Guardant360® CDx as a companion diagnostic for AstraZeneca’s ETCAMAH™—and its potential to advance more precise, proactive cancer care for certain patients with advanced #BreastCancer. Watch the full segment: bit.ly/4gU5JVN

With more screening options, we can reach the 54 million people who have forgone or delayed their critical #ColorectalCancer screening. Listen below to hear from our Co-CEO AmirAli Talasaz on how blood-based screening options like Shield™ have been proven to help close CRC screening gaps:

We’re heading to Seoul this week for #WCLC26, hosted by @IASLC Together with our research collaborators, we’ll present 20 abstracts highlighting advances in liquid biopsy across #LungCancer, including tissue-free MRD surveillance, treatment-response and resistance research, and investigational early-detection. Details: bit.ly/3SQYODJ